Christopher Drinjak

Christopher specialises in assisting lawyers to enhance their skills, win new instructions, manage client relationships and augment their international networks.

He has worked in senior business development roles based in the UK and in Germany, and currently is the business development lead for the firm's Life Sciences & Healthcare industry sector.

CV

Since 2019 Senior business development manager (Life sciences and healthcare), and Senior business development manager (Disputes and investigations, IP, Commercial tech and data, and Patents), Taylor Wessing

2011 - 2018 Senior practice development manager, Industry development (Global financial institutions group), and Interim head of business development Germany, Latham & Watkins

2001 - 2011 Business development manager (Finance and capital markets), Head of London L&DR business development, and Business development manager (Litigation and dispute resolution), Clifford Chance

职业发展

2011 - 2018 Senior practice development manager, Industry development (Global financial institutions group), and Interim head of business development Germany, Latham & Watkins

2001 - 2011 Business development manager (Finance and capital markets), Head of London L&DR business development, and Business development manager (Litigation and dispute resolution), Clifford Chance

教育

2001 Masters of business administration, International University, Germany

1996 M.A. in musicology, Michigan State University, US

1994 B.A. in German and B.A. in Music Performance, Michigan State University, US

Christopher Drinjak

专长

行业

CV

职业发展

教育

语言

Christopher Drinjak

专长

行业

CV

职业发展

教育

语言

Related news & insights

Cabinet decision on the Statutory Health Insurance Contribution Stabilization Act – Financial burdens on German pharmaceutical companies

Federal Administrative Court on the Delineation between Substance-Based Medical Devices and Medicinal Products

CJEU Advocate General on Distributors’ Obligations for Medical Devices

Federal Court of Justice Ruling on Public Advertising for Medical Cannabis on Online Platforms

Proposed Amendments to the EU Medical Device Regulation

The 2026 Pharma Package: A New Regulatory Framework for Medicinal Products in the EU

Impact of the new Biotech Act on Clinical Trials in the EU

Life Sciences Legal Lens – Vol. 1

Hungary opens health data infrastructure for AI development

Promotional activities for medical devices may qualify as agency even without direct negotiation power

相关人员

与我会面：